Ginkgo Bioworks
NEWS
Boston-based Ginkgo Bioworks calls itself “the organism company,” but what that means it uses microorganisms that it engineers across a broad range of markets. These engineered organisms churn out a wide variety of products. And the company has been on a frenzy of fundraising recently.
Fuels development of Synlogic’s growing pipeline of novel living medicines with technology access and $80.0 million equity investment at a premium
Ginkgo Bioworks bought Warp Drive Bio’s genome mining platform, which includes its genome mining team, technology and database.
Despite an ongoing lawsuit over alleged theft of intellectual property, San Francisco-based Twist Bioscience plans to go public with an $86 million initial public offering.
On August 29, Chicago-based Tempus, which focuses on data analytics for molecular and clinical data, announced it had raised $110 million in Series E financing. This brought total money raised so far to $320 million. This also gave the company a valuation of $2 billion.
When people hear the word “unicorn” they may think of the mythical horse with a polished horn protruding from its brow. But in the world of investing, the term unicorn refers to a startup company worth more than $1 billion.
Boston-based startup Catalog is one of the companies leading the way in the development of commercially viable DNA data storage.
Here is a look at the life science companies viewed as the most innovative in the world.
Ginkgo Bioworks, recently recognized by Forbes as one of 25 U.S. companies likely to hit a valuation of $1B or more, is well on its way.
JOBS
IN THE PRESS